FDA Approves First New Sunscreen Ingredient in 20 Years for Broader UV Protection
Bemotrizinol, long used safely in Europe, is now FDA-approved for US sunscreens, offering broad UVA and UVB protection with low skin absorption.
Summary
The FDA has approved bemotrizinol as a new active sunscreen ingredient — the first addition to the OTC sunscreen monograph since the late 1990s. Already used safely across Europe and globally for decades, bemotrizinol protects against both UVA and UVB rays and has low absorption through the skin. The FDA classifies it as generally recognized as safe and effective for adults and children six months and older. This regulatory update, fast-tracked under the CARES Act, expands consumer sunscreen choices and could prompt new product formulations. For health-conscious individuals focused on skin longevity and cancer prevention, this means access to more effective and potentially better-tolerated sunscreen options in the near future.
Detailed Summary
For the first time in roughly two decades, Americans will have access to a new active sunscreen ingredient. The FDA has finalized approval of bemotrizinol, expanding the list of permitted sunscreen actives under the over-the-counter monograph system. This matters because UV radiation is one of the most well-established drivers of skin aging, DNA damage, and skin cancer risk — all directly relevant to healthspan and longevity.
Bemotrizinol has been used safely in European and international sunscreen markets for years. It offers broad-spectrum protection against both ultraviolet A rays, which penetrate deeply and accelerate skin aging, and ultraviolet B rays, which are primarily responsible for sunburn and surface DNA damage. Critically, it demonstrates low dermal absorption, meaning minimal systemic exposure — a concern that has limited approval of other newer sunscreen actives in recent years.
The FDA classified bemotrizinol as generally recognized as safe and effective for use in adults and children as young as six months. It can be used at concentrations up to six percent in formulations. Approval was accelerated through the streamlined administrative order process established by the CARES Act, with the entire process from proposed order to final approval completed in under seven months.
For consumers focused on skin health and longevity, this opens the door to sunscreen formulations that may feel lighter, be more cosmetically elegant, or offer improved broad-spectrum protection compared to legacy US options like avobenzone or zinc oxide. European-style sunscreens have long been praised for superior texture and efficacy, partly due to access to ingredients like bemotrizinol.
Caveats remain: commercial products containing bemotrizinol are not yet on shelves, and real-world comparative efficacy data against existing US actives has not been publicly detailed in this regulatory announcement. Independent clinical comparisons will be needed.
Key Findings
- Bemotrizinol approved as first new US OTC sunscreen active ingredient since the late 1990s.
- Provides broad-spectrum UVA and UVB protection with documented low skin absorption levels.
- FDA classifies it safe and effective for adults and children aged 6 months and older.
- Approved at concentrations up to 6%, enabling flexible formulation by manufacturers.
- Fast-tracked under CARES Act streamlined process, going from proposal to approval in under 7 months.
Methodology
This is an official FDA press release announcing a regulatory decision, representing high-authority primary source information. The evidence basis is the FDA's review of an OTC monograph order request submitted by DSM Nutritional Products LLC, incorporating existing international safety data and public comment. No new clinical trial data is presented directly in the release.
Study Limitations
The press release does not provide head-to-head efficacy comparisons with existing US sunscreen actives. Timeline for commercial product availability is unspecified. Long-term systemic safety data specific to US populations was not detailed, and independent review of the full FDA order is recommended for clinical depth.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.